EVHC) and certain of its officers, on behalf of shareholders who purchased Envision securities between March 2, 2015 and July 21, 2017, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: http://www.bgandg.com/evhc.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Envision's operating subsidiary, EmCare Holdings, Inc., routinely arranged for patients who sought treatment at in-network facilities to be treated by out-of-network physicians; (2) EmCare accordingly billed these patients at higher rates than if the patients had received treatment from in-network physicians; (3) Envision's statements attributing EmCare's Class Period growth to other factors were therefore false and/or misleading; (4) Envision's EmCare revenues were likely to be unsustainable after the foregoing conduct came to light; and (5) consequently, Envision's public statements were materially false and misleading at all relevant times.

On July 24, 2017, The New York Times published an article stating that doctors associated with Envision's subsidiary EmCare Holdings Inc. were extremely likely to engage in "surprise billing," in which patients who go to in-network hospitals are treated by out-of-network doctors and then billed at higher rates. Following this news, Envision stock dropped $2.33 per share, or 3.72%, to close at $60.28 on July 24, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: http://www.bgandg.com/evhc, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Envision, you have until October 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 473295

"/> SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Envision Healthcare Corporation (EVHC) and Lead Plaintiff Deadline – October 3, 2017 « MarketersMedia – Press Release Distribution Services – News Release Distribution Services

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Envision Healthcare Corporation (EVHC) and Lead Plaintiff Deadline – October 3, 2017

NEW YORK, NY / ACCESSWIRE / September 13, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Envision Healthcare Corporation ("Envision" or the "Company") (NYSE: EVHC) and certain of its officers, on behalf of shareholders who purchased Envision securities between March 2, 2015 and July 21, 2017, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: http://www.bgandg.com/evhc.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Envision's operating subsidiary, EmCare Holdings, Inc., routinely arranged for patients who sought treatment at in-network facilities to be treated by out-of-network physicians; (2) EmCare accordingly billed these patients at higher rates than if the patients had received treatment from in-network physicians; (3) Envision's statements attributing EmCare's Class Period growth to other factors were therefore false and/or misleading; (4) Envision's EmCare revenues were likely to be unsustainable after the foregoing conduct came to light; and (5) consequently, Envision's public statements were materially false and misleading at all relevant times.

On July 24, 2017, The New York Times published an article stating that doctors associated with Envision's subsidiary EmCare Holdings Inc. were extremely likely to engage in "surprise billing," in which patients who go to in-network hospitals are treated by out-of-network doctors and then billed at higher rates. Following this news, Envision stock dropped $2.33 per share, or 3.72%, to close at $60.28 on July 24, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: http://www.bgandg.com/evhc, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Envision, you have until October 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 473295

NEW YORK, NY / ACCESSWIRE / September 13, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Envision Healthcare Corporation ("Envision" or the "Company") (NYSE: EVHC) and certain of its officers, on behalf of shareholders who purchased Envision securities between March 2, 2015 and July 21, 2017, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: http://www.bgandg.com/evhc.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Envision's operating subsidiary, EmCare Holdings, Inc., routinely arranged for patients who sought treatment at in-network facilities to be treated by out-of-network physicians; (2) EmCare accordingly billed these patients at higher rates than if the patients had received treatment from in-network physicians; (3) Envision's statements attributing EmCare's Class Period growth to other factors were therefore false and/or misleading; (4) Envision's EmCare revenues were likely to be unsustainable after the foregoing conduct came to light; and (5) consequently, Envision's public statements were materially false and misleading at all relevant times.

On July 24, 2017, The New York Times published an article stating that doctors associated with Envision's subsidiary EmCare Holdings Inc. were extremely likely to engage in "surprise billing," in which patients who go to in-network hospitals are treated by out-of-network doctors and then billed at higher rates. Following this news, Envision stock dropped $2.33 per share, or 3.72%, to close at $60.28 on July 24, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: http://www.bgandg.com/evhc, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Envision, you have until October 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 473295

Source URL: https://marketersmedia.com/shareholder-alert-bronstein-gewirtz-grossman-llc-reminds-investors-of-class-action-against-envision-healthcare-corporation-evhc-and-lead-plaintiff-deadline-october-3-2017-2/238940

Source: AccessWire

Release ID: 238940


Latest News